Biotech Was a Graveyard. Now It Might Be the Trade of the Decade.
For four years, biotech was where capital went to die.
From February 2021 to late 2023, the SPDR Biotech ETF (XBI) collapsed from ~$174 to ~$66 -- a brutal 62% drawdown. IPOs were worse. According to Renaissance Capital, 2024 biotech IPOs averaged -52% returns. Only 2 of 18 sizable deals traded above their offer price. Over five years, biotech IPOs averaged -41%.
BioPharma Dive described the market as "Groundhog Day."
Evidence Investor called it "30 years of disappointment."
If you allocated to biotech between 2021 and 2024, you were punished for it.
And then, almost quietly, something changed.
Not just in price.
In the science.
The Turn: Not Just Capital -- Breakthrough Density
In Q1 2026, a thread by @mgoesdistance went viral for listing 10 biotech breakthroughs in a single quarter.
At first glance, it looked like optimism bias.
Then you read the actual data.
1. The First Human Trial Aiming to Reverse Aging
On January 28, 2026, Life Biosciences received FDA clearance for ER-100 -- the first human trial using partial epigenetic reprogramming.
Here's what that actually means:
In mice, researchers have shown that you can "reset" cellular age by modifying epigenetic markers -- essentially rolling back the biological clock without changing DNA. It's been theoretical for years.
Now it's in humans.
The trial targets optic neuropathies, but the implication is broader: aging is no longer philosophically immutable. It is experimentally modifiable.
That's not a product launch.
That's a paradigm shift.
2. Psychedelics Cross the Regulatory Rubicon
On February 17, Compass Pathways announced its second successful Phase 3 trial for COMP360 psilocybin in treatment-resistant depression (BusinessWire).
Two Phase 3 wins means FDA submission.
For decades, psychedelics lived in the cultural underground. Now we're watching the first likely approval of a psychedelic therapy for depression in modern U.S. medicine.
This is not just a drug win.
It's a category legitimization event.
3. Cancer Cells... Reversed
At KAIST in South Korea, researchers published evidence that colon cancer cells can be reverted to normal cells instead of destroyed (News-Medical).
Oncology has always been binary: kill the tumor.
This introduces a third axis: rehabilitate it.
If reproducible across tumor types, that's not incremental progress -- that's a new therapeutic modality.
4. Turning Tumors into Pork
In February, a team from Guangxi Medical University published in Cell a therapy that forces cancer cells to express pig antigens, triggering hyperacute immune rejection -- the same violent response that rejects mismatched organ transplants.
They call it NDV-GT. Disease control rate: 90% in 23 advanced cancer patients.
The South China Morning Post summarized it simply: Chinese scientists are "turning tumors into pork."
It sounds absurd.
Until you realize it weaponizes one of the most powerful immune reactions known to biology.
5. CAR-T -- But for Aging
CAR-T therapies revolutionized oncology by engineering immune cells to attack cancer.
Now, researchers at Cold Spring Harbor have shown in Nature Aging that engineered CAR-T cells can restore youthful regenerative capacity in aging intestines (Nature Aging).
Not cancer treatment.
Aging treatment.
If this line of research expands beyond gut regeneration, the longevity thesis shifts from speculative to clinical.
Meanwhile, Capital Came Back
Science alone doesn't move markets. Liquidity does.
In January and February 2026:
- Eikon Therapeutics raised $381M
- Generate Biomedicines raised $400M
- Agomab raised $200M
- Monte Rosa raised $300M
Endpoints News called it:
"Biotech's groove is back."
XBI hit a 52-week high, up nearly 100% from its lows.
Lower rates helped. M&A returned. But the deeper driver is this:
Breakthrough density increased.
When science clusters, capital follows.
Why This Might Actually Be Different
Biotech has burned investors before. This isn't the first "renaissance."
So what's structurally new?
1. AI Is Now Inside the Lab
Companies like Generate Biomedicines, Recursion, and Xaira aren't layering AI onto biotech -- they're building programmable biology platforms.
Drug discovery timelines are compressing.
Hypothesis cycles are accelerating.
Iteration costs are falling.
This looks eerily similar to software in the early cloud era.
2. Platformization of Biology
CRISPR. mRNA. CAR-T. Oncolytic viruses.
These are no longer single assets. They're modular toolkits.
Once you can program immune cells or edit genes with reliability, the pipeline becomes multiplicative.
The industry may be shifting from "one molecule, one bet" to "platform, many shots on goal."
3. Longevity Is Crossing Into Phase 1
Altos Labs raised $3B. Retro Biosciences raised $180M. ER-100 just entered humans.
For decades, longevity was an idea.
Now it's a line item in clinical development.
That changes the total addressable market in ways most models don't capture.
The Real Question
Biotech destroyed capital from 2021 to 2024 because it was:
- Duration-sensitive in a rising rate world
- Overcapitalized from the COVID bubble
- Dependent on IPO liquidity
- Rates stabilize
- AI accelerates biological iteration
- Breakthrough density increases
- Platform technologies mature
- Capital reopens
You get a regime change.
The Investor Frame
This feels less like a dead-cat bounce and more like AI circa 2012-2015.
Early.
Misunderstood.
Compounding quietly.
The mistake from 2021 wasn't believing in biotech.
It was believing too early, in a hostile macro regime, without platform leverage.
The opportunity in 2026 may be different:
- Platform-native biotech
- AI-first discovery companies
- Longevity infrastructure
- Diagnostics as regulatory leverage plays
But graveyards sometimes sit on top of oil fields.
The question isn't whether biotech will define this decade.
The question is whether you'll recognize it before consensus does.
